北京市春立正达医疗器械股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 相关日期 证券代码：688236 证券简称：春立医疗 公告编号：2025-031 每股现金红利0.049元（含税） | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/7/31 | 2025/8/1 | 2025/8/1 | H 股股东的现金分红有关情况详见本公司分别于 2025 年 3 月 28 日、2025 年 5 月 28 日及 2025 年 6 月 27 日在香港联交所网站（www.hkex.com.hk）发布的相关 公告及通函。 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 6 月 26 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股 东。 是否涉及差异 ...

Core Viewpoint - Spring Medical has shown significant stock performance, with a year-to-date increase of 73.18%, outperforming the Hang Seng Index by 27.31% [2] Financial Performance - As of March 31, 2025, Spring Medical reported total revenue of 230 million yuan, a year-on-year increase of 3.6% - The net profit attributable to shareholders was 58.071 million yuan, reflecting a growth of 5.2% - The gross profit margin stood at 66.69%, while the debt-to-asset ratio was 17.11% [2] Market Position and Valuation - Currently, there are no institutional investment ratings for Spring Medical - The company's price-to-earnings (P/E) ratio is 41.21, ranking 45th in the healthcare equipment and services industry, which has an average P/E ratio of -1.39 and a median of 1.36 [3] Company Overview - Founded in 1998, Spring Medical focuses on high-end medical device development, offering a full range of orthopedic products including joint, spine, sports medicine, and trauma products - The company has 124 medical device registrations and continues to expand its product line to meet diverse market needs [3][4] Research and Development - Spring Medical boasts a multidisciplinary team with over 20 years of industry experience, including experts in mechanical design, materials science, biomechanics, and clinical medicine - The company has received multiple qualifications, including being recognized as a national high-tech enterprise and a champion enterprise in manufacturing [4] Innovation and Market Strategy - As a leading player in China's orthopedic industry, Spring Medical has filled domestic market gaps with innovative products, enhancing its core competitiveness and industry recognition - The company aims to solve key technical challenges in the industry and promote independent innovation in the joint field [5]

Group 1 - The core viewpoint of the news is the performance and holdings of the Ping An Low Carbon Economy Mixed A fund, which has shown positive growth in recent months and has a significant portion of its assets allocated to top-performing stocks [1][3]. - As of July 23, 2025, the latest net value of the Ping An Low Carbon Economy Mixed A fund is 1.0878 yuan, reflecting a growth of 1.04%. The fund has achieved a return of 5.83% over the past month, 18.07% over the past six months, and 17.20% year-to-date [1]. - The fund's top ten stock holdings account for a total of 68.78%, with notable investments in companies such as Gigabyte (9.02%), Gree Electric Appliances (8.50%), and Xpeng Motors (8.33%) [1]. Group 2 - The Ping An Low Carbon Economy Mixed A fund was established on August 10, 2020, and as of June 30, 2025, it has a total scale of 1.427 billion yuan, managed by fund manager He Jie [1]. - He Jie has a background in finance, holding a master's degree from the University of Augsburg in Germany, and has held various positions in investment management and research prior to joining Ping An Fund Management Company in August 2021 [2].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 本公告之目的為就該等年報提供補充資料。 (1) 2022年年報的補充資料 除2022年年報所載合併財務報表附註十三（三）的披露資料外，本公司謹此 提供下列有關並非董事的主要行政人員薪酬之額外資料： 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：1858） 有關2022年、2023年及2024年年報的補充公告 茲提述(1)北京市春立正達醫療器械股份有限公司（「本公司」，連同其附屬公司 統稱「本集團」）截至2022年12月31日止年度的年度報告（「2022年年報」）；(2)本 集團截至2023年12月31日止年度的年度報告（「2023年年報」）；及(3)本集團截至 2024年12月31日止年 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：1858） 有關2022年、2023年及2024年年報的補充公告 除2022年年報所載合併財務報表附註十三（三）的披露資料外，本公司謹此 提供下列有關並非董事的主要行政人員薪酬之額外資料： 本公司主要行政人員（並非董事）截至2022年12月31日止年度的薪酬載列如 下： 茲提述(1)北京市春立正達醫療器械股份有限公司（「本公司」，連同其附屬公司 統稱「本集團」）截至2022年12月31日止年度的年度報告（「2022年年報」）；(2)本 集團截至2023年12月31日止年度的年度報告（「2023年年報」）；及(3)本集團截至 2024年12月3 ...

7月21日，春立医疗今日收盘19.88元，上涨2.74%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到59.64倍，总市值76.25亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均52.71倍，行业中值37.14倍，春立医疗排 名第89位。 截至2025年一季报，共有8家机构持仓春立医疗，其中基金8家，合计持股数642.51万股，持股市值1.19 亿元。 北京市春立正达医疗器械股份有限公司的主营业务是植入性骨科医疗器械的研发、生产与销售。公司的 主要产品是脊柱类、创伤类、关节类、运动医学类、骨修复材料类植入物、手术器械产品、富血小板血 浆（PRP）制备用套装、封闭创伤负压引流套装。2024年获国家工信部认定的人工关节假体制造业单项 冠军企业。 最新一期业绩显示，2025年一季报，公司实现营业收入2.30亿元，同比3.60%；净利润5807.11万元，同 比5.20%，销售毛利率66.69%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13春立医疗59.6461.012.6576.25亿行业平均 52.7148.294.64110.80亿行业中值37.1437.062. ...

Group 1 - The core viewpoint of the articles highlights that Chunzhi Medical's stock closed at 19.35 yuan, down 3.25%, with a rolling PE ratio of 58.05 times and a total market value of 7.422 billion yuan [1] - The average PE ratio for the medical device industry is 52.34 times, with a median of 36.99 times, placing Chunzhi Medical at the 89th position in the industry ranking [1] - As of the first quarter of 2025, two institutions hold shares in Chunzhi Medical, with a total of 5.0428 million shares valued at 0.94 billion yuan [1] Group 2 - Chunzhi Medical specializes in the research, production, and sales of implantable orthopedic medical devices, including spinal, trauma, joint, sports medicine, bone repair materials, surgical instruments, and PRP preparation kits [1] - The latest performance report for the first quarter of 2025 shows that the company achieved an operating income of 230 million yuan, a year-on-year increase of 3.60%, and a net profit of 58.0711 million yuan, a year-on-year increase of 5.20%, with a gross profit margin of 66.69% [1] - The company was recognized as a champion enterprise in the artificial joint prosthesis manufacturing industry by the Ministry of Industry and Information Technology in 2024 [1]

Core Viewpoint - Spring Medical's stock closed at 19.17 yuan, up 1.75%, with a rolling PE ratio of 57.51, marking a new low in 281 days, and a total market capitalization of 7.353 billion yuan [1] Company Summary - Spring Medical specializes in the research, production, and sales of implantable orthopedic medical devices, including spinal, trauma, joint, sports medicine, bone repair materials, surgical instruments, and PRP preparation kits [1] - The company was recognized as a champion enterprise in the artificial joint prosthesis manufacturing industry by the Ministry of Industry and Information Technology in 2024 [1] - For Q1 2025, Spring Medical reported revenue of 230 million yuan, a year-on-year increase of 3.60%, and a net profit of 58.071 million yuan, up 5.20%, with a gross profit margin of 66.69% [1] Industry Summary - The average PE ratio for the medical device industry is 51.87, with a median of 37.48, placing Spring Medical at the 88th position in the industry ranking [1] - The industry average market capitalization is 10.806 billion yuan, while the median is 5.267 billion yuan [2]

Investment Rating - The report maintains an optimistic outlook on the pharmaceutical industry, particularly for 2025, suggesting a potential for diverse investment opportunities as the sector recovers from low valuations and public fund allocations [10]. Core Insights - The pharmaceutical sector is currently experiencing low valuations, with public funds under-allocating to this area. The report anticipates a recovery driven by macroeconomic factors and significant product launches [10]. - The report emphasizes a shift in the innovative drug sector from quantity to quality, highlighting the importance of differentiated products and international expansion for profitability [10]. - The medical device sector is seeing a rebound in bidding volumes, particularly in imaging equipment, and is expected to benefit from domestic product upgrades and international market expansion [10]. - The report identifies a growing trend in the CXO and life sciences services sector, with expectations for increased investment and a recovery in demand [10]. - The traditional Chinese medicine sector is projected to benefit from policy changes and market dynamics, with specific companies recommended for investment based on their unique product offerings and market positions [12]. Summary by Sections Market Review - The report notes a 1.80% increase in the CITIC Pharmaceutical Index, outperforming the CSI 300 Index by 0.98 percentage points, ranking 16th among 30 sectors [7]. - The top-performing stocks include Frontline Bio-U, MediWest, and Lianhuan Pharmaceutical, while the worst performers include ST Weiming and Innovent Biologics [7]. Overall Perspective and Investment Themes - The report suggests that the pharmaceutical industry is poised for growth, with a focus on innovative drugs, medical devices, and traditional Chinese medicine. Specific companies are highlighted for their potential in these areas [10][12]. - The report also discusses the implications of policy changes and market trends for the pharmaceutical and medical device sectors, indicating a favorable environment for investment [10][12]. Company-Specific Insights - Companies like Baiyi, Xinda, and Kangfang are highlighted for their innovative drug pipelines and potential for growth in the coming years [10][12]. - The report provides detailed insights into the clinical progress of various drugs across different companies, indicating a robust pipeline that could drive future revenue [13][20][24][30][35][38].

Core Viewpoint - The controlling shareholder, Shi Chunbao, has increased his stake in Chunli Medical from 55.92% to 56.22%, triggering a 1% threshold change in equity [1][2]. Group 1: Shareholder Information - The controlling shareholder is Shi Chunbao, with an increase in shareholding from 11,904.5093 thousand shares (31.04%) to 12,020.9043 thousand shares (31.34%) [2]. - The consistent shareholder, Yue Shujun, maintained her stake at 9,544.7900 thousand shares (24.88%) [2]. - The total shareholding of both shareholders increased from 21,449.2993 thousand shares (55.92%) to 21,565.6943 thousand shares (56.22%) [2]. Group 2: Equity Change Details - The equity change occurred between May 6, 2025, and July 10, 2025, through self-funded purchases via centralized bidding [1][2]. - The increase in shareholding does not violate any prior commitments or plans made by the shareholders [1]. - The change does not trigger mandatory tender offer obligations under relevant regulations [1]. Group 3: Regulatory Compliance - The equity change does not require the disclosure of an equity change report as per the "Measures for the Administration of Acquisitions of Listed Companies" and other relevant regulations [2]. - The company will continue to monitor the situation and fulfill its information disclosure obligations as required [2].